Most Read Articles
04 Feb 2019
The carbon-chain length of saturated fatty acids appears to be an important factor in determining its role in cardiovascular health, a recent study has found.
6 days ago
Olanzapine confers a modest therapeutic effect on weight compared with placebo in adult outpatients with anorexia nervosa, a study has shown. However, it does not appear to offer significant benefit for psychological symptoms.
Pearl Toh, 3 days ago
A latest study at ISC 2019 shows that even patients with large-core stroke damage can have a good outcome after mechanical clot removal with endovascular thrombectomy (EVT), depending on the size of the infarct and time lapses between stroke onset and treatment.
Jairia Dela Cruz, 04 Feb 2019
Treatment with secukinumab results in a higher rate of remission or low-disease activity at week 16 in patients with psoriatic arthritis as compared with placebo, according to a posthoc analysis of the FUTURE 2 study. This effect is sustained at 2 years and is evident in both tumour necrosis factor inhibitor-experienced and -naïve patients.

Bariatric surgery vs medical treatment leads to lower long-term mortality

04 Dec 2018

Long-term all-cause, cardiovascular-caused and cancer-caused mortality are lower in obese patients who have received biliopancreatic diversion (BPD) and biliointestinal bypass (BIBP) compared to those who have received nonsurgical medical weight-loss treatment, a recent study has shown.

“Malabsorptive bariatric surgery (BS) significantly reduces long-term mortality in severely obese patients,” the investigators said.

Observation period lasted for a mean 12.1±3.41 years. BS vs nonsurgical patients had reduced all-cause mortality (7.2 percent vs 12.9 percent; χ2, 11.25; p=0.001; hazard ratio [HR], 0.64; 95 percent CI, 0.43–0.93; p=0.019).

Surgery patients also had significantly less frequent cardiovascular (HR, 0.26; 0.09–0.72; p=0.003) and cancer (HR, 0.21; 0.09–0.45) causes of death compared to those on nonsurgical treatment (p<0.001).

Another aspect of the study showed that patients who underwent malabsorptive BS showed less incident cases of diabetes, cardiovascular diseases, hyperlipidaemia, oculopathy and cancer compared with controls receiving medical treatment. [Obes Surg 2018;doi:10.1007/s11695-018-3601-5]

The present study sought to analyse long-term mortality in obese patients receiving malabsorptive BS (BPD and BIBP) compared to medical treatment of obesity.

The investigators collected medical records of 1,877 obese patients (body mass index [BMI], >35 kg/m2) aged 18–65 years undergoing BS (n=472,111 with diabetes) or nonsurgical medical treatment (n=1,405,385 with diabetes), during the period 1999–2008. Nonsurgical patients were matched for age, sex, BMI and blood pressure. Life status and causes of death were determined through December 2016.

Kaplan-Meier plots and Cox regression analyses were used to compare survival across surgery and nonsurgical patients.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Doctor - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
04 Feb 2019
The carbon-chain length of saturated fatty acids appears to be an important factor in determining its role in cardiovascular health, a recent study has found.
6 days ago
Olanzapine confers a modest therapeutic effect on weight compared with placebo in adult outpatients with anorexia nervosa, a study has shown. However, it does not appear to offer significant benefit for psychological symptoms.
Pearl Toh, 3 days ago
A latest study at ISC 2019 shows that even patients with large-core stroke damage can have a good outcome after mechanical clot removal with endovascular thrombectomy (EVT), depending on the size of the infarct and time lapses between stroke onset and treatment.
Jairia Dela Cruz, 04 Feb 2019
Treatment with secukinumab results in a higher rate of remission or low-disease activity at week 16 in patients with psoriatic arthritis as compared with placebo, according to a posthoc analysis of the FUTURE 2 study. This effect is sustained at 2 years and is evident in both tumour necrosis factor inhibitor-experienced and -naïve patients.